The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
ApexOnco Front Page
Recent articles
Tecvayli and Hernexeos might get speedy approval decisions.
The company’s AN9025 will shortly enter phase 1.
But the group still hopes to get IGV-001 approved based on overall survival data.
A more comprehensive dataset on JANX007 sends the group’s stock down.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
The agency approved eight oncology products over the month.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
